Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference

Rhea-AI Summary

Yumanity Therapeutics (NASDAQ: YMTX) announced that CEO Richard Peters, M.D., Ph.D., will present at the H.C. Wainwright 23rd Global Investment Conference. The presentation will be accessible on-demand through the conference portal and the company’s website starting September 13 at 7 a.m. EDT.

Yumanity focuses on developing therapies for neurodegenerative diseases, with its leading candidate, YTX-7739, currently in Phase 1 clinical trials for Parkinson’s disease. The company also has programs targeting conditions like Alzheimer’s and ALS.

BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 23^rd Global Investment Conference.

The presentation will be available on-demand via the conference portal and through the Company's website at www.yumanity.com/events beginning at 7 a.m. EDT, September 13.

About Yumanity Therapeutics
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson’s disease. Yumanity’s drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases. Yumanity’s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. For more information, please visit www.yumanity.com.

Investors:
Burns McClellan, Inc.
Lee Roth
lroth@burnsmc.com
(212) 213-0006

Media:
Burns McClellan, Inc.
Robert Flamm, Ph.D. / Harrison Wong
rflamm@burnsmc.com / hwong@burnsmc.com
(212) 213-0006 ext. 364 / 316

FAQ

When will Yumanity Therapeutics present at the H.C. Wainwright 23rd Global Investment Conference?

Yumanity Therapeutics will present at the conference on September 13, starting at 7 a.m. EDT.

What is Yumanity Therapeutics' lead drug candidate?

The lead drug candidate of Yumanity Therapeutics is YTX-7739, currently in Phase 1 clinical development for Parkinson’s disease.

What diseases does Yumanity Therapeutics focus on?

Yumanity Therapeutics focuses on neurodegenerative diseases, including Parkinson’s, Alzheimer’s, and ALS.

Where can I access Yumanity Therapeutics' presentation?

The presentation can be accessed on-demand via the conference portal and Yumanity Therapeutics' website.

What is the stock symbol for Yumanity Therapeutics?

The stock symbol for Yumanity Therapeutics is YMTX.